DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06764056

METAfoie

Not yet recruitingPhase NA

Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Through an Individualized Nutritionnal Approach and Semaglutide Therapy.

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

120

estimated

Study population

MASH / NAFLD / liver fibrosis, Obesity / overweight

Key I/E criterion

•BMI 30-50

Primary endpoints

•Liver Steatosis•Liver stiffness (VCTE), change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06764056
Org study ID2025-4271

Timeline

Milestones

Study first posted2025-01-08actual
Last update posted2025-01-08actual
Study start2025-01estimated (month precision)
Primary completion2026-05estimated (month precision)
Study completion2026-05estimated (month precision)

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

MASH / NAFLD / liver fibrosisObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Body mass index between 30 and 50 kg/m2;
•Stade 2 or 3 (S2 or S3) hepatic steatosis with or without liver fibrosis.

Exclusion criteria

•Type 1 diabetes diagnosis;
•Alcohol consumption exceeding recommendations [>140 g/week (women) and >210 g/week (men)];
•Known chronic hepatic disease non-steatotic at the entry of the study (Wilson's disease, hemochromatosis, alpha-1-antitrypsin deficiency, viral hepatitis, auto-immune hepatitis, etc.);
•Pharmacological treatment targeting obesity active or ended in the last 3 months;
•Bariatric surgery;
•Gastro-intestinal pathologies (GI cancers, IBD, etc.);
•Capsulated probiotics consumption;
•Antibiotic treatment in the last 3 months;
•Pregnancy;
•Cirrhosis diagnosis (hepatic decompensation).

Endpoints (13)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

MASH / liver
6
Glycemic / diabetes
3
Cardiometabolic biomarkers
3
Other (unclassified)
1

Glycemic / diabetes

3 endpoints
Secondary/protocol endpoint

Glucose

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Insulin

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

concentration, descriptive

Secondary/protocol endpoint

Glycated hemoglobin

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

MASH / liver

6 endpoints
Primary/protocol endpoint

Liver Steatosis

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

categorical status, improvement

Primary/protocol endpoint

Liver Stiffness

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

Liver stiffness (VCTE), change

change from baseline, improvement

Secondary/protocol endpoint

Liver function (biochemistry)

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

descriptive, improvement

Secondary/protocol endpoint

Liver enzymes

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

change from baseline, improvement

Secondary/protocol endpoint

Fatty liver index (FLI)

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

threshold achievement, improvement

Secondary/protocol endpoint

Fibrosis-4 index (FIB-4)

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

threshold achievement, improvement

Cardiometabolic biomarkers

3 endpoints
Secondary/protocol endpoint

Lipid panel

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

descriptive, improvement

Secondary/protocol endpoint/low confidence

Change from Baseline in blood lipids and metabolites

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

change from baseline, improvement

Secondary/protocol endpoint

C-reactive protein

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Change from Baseline in the gut microbiota diversity

Time frame:From enrollment to the end of the clinical trial at 12 months (for 4 visits)

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.